ArticleFrontiers in pharmacology2025
Comparing tacrolimus level monitoring in peripheral blood mononuclear cells and whole blood within one year after kidney transplantation: a single-center, prospective, observational study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ABCC2 rs2273697 is an independent determinant of tacrolimus intra-patient variability during the first year after kidney transplantation.International journal of clinical pharmacy · 2026Article
- Elevated tacrolimus exposure variability predicts transplant renal insufficiency.Frontiers in immunology · 2026Article
- Timing matters: tacrolimus intra-patient variability within the initial seven months forecastsFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tacrolimus, a key immunosuppressant for kidney transplant recipients, is traditionally monitored through whole-blood trough concentrations. However, this approach may not accurately reflect lymphocyte tacrolimus levels, limiting its predictive value for allograft function and rejection. Monitoring tacrolimus levels in peripheral blood mononuclear cells (PBMCs) offers a potentially more precise alternative, though its clinical value remains unclear. This study aimed to compare tacrolimus intra-patient variablity (IPV), allograft function, and Methods: This single-center, prospective, observational, non-interventional study enrolled kidney transplant recipients between November 2021 and February 2023. At six follow-up time points after transplantation (Day 7, Day 14, Month 1, Month 3, Month 6, and Month 12), tacrolimus levels in PBMCs and whole blood were measured, and IPVs in both matrices were calculated. Pearson's or Spearman's correlation analyses were used to evaluate (1) the relationship between tacrolimus levels in PBMCs and whole blood, (2) their association with allograft function, and (3) the correlation of tacrolimus IPV with allograft function and dnDSA status. Results: A total of 60 kidney transplant recipients were included. Within 1-year post-transplantation, the PBMC tacrolimus levels were 3.6% of whole-blood levels (P < 0.01). Tacrolimus levels in PBMCs and whole blood showed positive correlations across six-time points, with statistically significant correlations on Day 7, Day 14, Month 3, and Month 6 (P < 0.05). Notably, PBMC tacrolimus levels demonstrated stronger associations with creatinine clearance and estimated glomerular filtration rate at multiple timepoints compared to whole-blood measurements. Patients with dnDSA exhibited significantly higher IPV in PBMC tacrolimus levels than dnDSA-negative counterparts (P < 0.05), a pattern not observed in whole-blood analysis. Conclusion: Monitoring tacrolimus levels and IPVs in PBMCs provides greater insight into allograft function and dnDSA status than whole-blood measurements. These findings suggest that PBMC-based tacrolimus monitoring may enhance clinical value in managing kidney transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.